INS and type 1 diabetes mellitus: Early open-label studies in psoriasis similarly report reductions in plaque severity linked to normalization of the Th17/Treg ratio, and vitamin-D-primed AASCs administered at the onset of type 1 diabetes have reduced exogenous insulin requirements, consistent with partial preservation of β-cell mass.